Conference Reports for NATAP

13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil Back

Zero HIV acquisitions with twice-yearly subcutaneous lenacapavir for PrEP during 52 weeks of open-label extension in PURPOSE 1       IAS 2026 Rio, Brazil   N. KIWANUKA